Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma.
Department of Hematology, Hospital Doctor José Molina Orosa, Arrecife de Lanzarote, Spain Department of Hematology, Hospital Universitario La Princesa, Madrid, Spain Department of Hematology, Hospital General de Ciudad Real, Ciudad Real, Spain Department of Hematology, Hospital Universitario de Canarias, Tenerife, Spain Department of Hematology, Hospital Virgen de la Victoria, Málaga, Spain.European Journal Of Haematology (impact factor: 2.61). 05/2011; 87(3):281-4. DOI:10.1111/j.1600-0609.2011.01644.x pp.281-4
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.